ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Diazepam

Also written as “diazepam nasal spray”, “NRL-1” and “Diazepam Nasal Spray [Valtoco]”.

Its studies are mostly in Epilepsy · Seizures · Drug Resistant Epilepsy, led by 4 companies.

Drug pageDiazepam: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 20119 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acorda Therapeuticsits history only40 open or runningphase 2since Aug 12, 2011Aug 12, 2011none ahead
Neurelis30 open or runningphase 3since Mar 17, 2016Mar 17, 2016none ahead
Pfizerits history only10 open or runningphase 3since Apr 27, 2006Apr 27, 2006none ahead
UCBits history only10 open or runningphase 1since Jun 5, 2025Jun 5, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Neurelis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 17, 2016First study: phase 1 study in EpilepsyFirst studyNCT02724423 · 57 enrolled · United States
  2. Mar 17, 2016Phase 3 study in SeizuresNCT02721069 · 175 enrolled · United States
  3. Sep 15, 2021Phase 2 study in EpilepsyNCT05076838 · 36 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamruleEli Lillyphase 497
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
brexanoloneruleSupernus Pharmaceuticalsphase 414

Studies

All 3 Neurelis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05076838Epilepsy · United States2CompletedMar 11, 202536
NCT02724423Epilepsy · United States1CompletedApr 10, 201957
NCT02721069Seizures · United States3CompletedJun 17, 2020175

How it is read

Names in the registry

  • “diazepam nasal spray”, 3 entries
  • “Diazepam”, 2 entries
  • “NRL-1”, 2 entries
  • “Diazepam Nasal Spray [Valtoco]”, 1 entry
  • “Vanquix Auto-Injector (Diazepam Injection)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.